Filing Overview
Registrant: Tivic Health Systems, Inc. The request metadata identifies Valion Bio, Inc., but the provided Form 8-K is filed by Tivic Health Systems, Inc. (Nasdaq: TIVC).
Report date: December 16, 2021; the filing was signed December 22, 2021. The filing includes events through December 21, 2021.
Business Context and Material Developments
- The company develops bioelectronic technologies, including technologies being evaluated as potential alternatives to opioids for post-surgery pain management.
- The company moved its principal place of business from Newark to 25821 Industrial Blvd., Suite 100, Hayward, California, where it subleases approximately 9,091 square feet. Material sublease terms were previously disclosed in a November 18, 2021 Form 8-K.
- The company is preparing, in collaboration with the Icahn School of Medicine at Mount Sinai, for a double-blind, randomized, controlled clinical trial evaluating its technologies for post-surgery pain management. The trial is expected to commence in the near term, but no specific start date is provided.
- Mindgruve was appointed as the company’s digital marketing agency of record, announced in a December 20, 2021 press release furnished as Exhibit 99.1.
Compensation and Management Changes
Board Compensation Plan
On December 16, 2021, the board approved the company’s first formal board compensation plan. Payments will be made in equal quarterly installments.
| Position | Annual Compensation |
|---|---|
| All directors | $35,000 retainer |
| Chairman of the Board | $15,000 |
| Chairman of the Audit Committee | $13,000 |
| Chairman of the Compensation Committee | $9,000 |
| Chairman of the Nominating and Governance Committee | $6,000 |
Chief Operating Officer Appointment
On December 21, 2021, Ryan Sabia was appointed Chief Operating Officer after serving as Vice President of Sales and Operations since March 2021.
- No formal employment agreement is disclosed.
- Base salary: $250,000 per year.
- Potential annual incentive bonus: up to 25% of base salary, at the board’s discretion, based on company milestones, profitability, and other factors.
- The filing reports no related-person transactions, family relationships, or other arrangements requiring disclosure in connection with the appointment.
Financial Metrics, Liquidity, and Debt
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other financial statement metrics. It also does not disclose the expected cost of the clinical trial, marketing engagement, relocation, or compensation plan.
Outlook, Risks, and Unusual Items
- The expected clinical trial commencement is forward-looking and remains subject to preparation, operational execution, and other risks; no enrollment targets, approval milestones, timing details, or trial budget are provided.
- The potential COO bonus is discretionary and contingent on milestones and profitability, so the ultimate compensation expense is uncertain.
- The new board compensation plan creates recurring annual compensation obligations that did not previously exist.
- The filing contains customary forward-looking statement warnings regarding risks and uncertainties that could cause actual results to differ materially from expectations.
Key Facts for Investors to Verify
- Confirm the correct issuer: the supplied filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review the November 18, 2021 Form 8-K for the terms and obligations of the Hayward office sublease.
- Monitor the Mount Sinai clinical trial for commencement, registration, enrollment, results, and regulatory developments.
- Assess the recurring cost of the new board compensation plan and the potential COO incentive bonus.
- Review Exhibit 99.1 and subsequent filings for details regarding Mindgruve’s engagement and related marketing expenses.